Protagonist Therapeutics (PTGX) to Report Q3 Results: Wall Street Expects Earnings Growth

Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • 14 hours ago

Why Protagonist Therapeutics (PTGX) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • 14 hours ago

Wall Street Analysts See a 25.34% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?

The mean of analysts' price targets for Protagonist Therapeutics (PTGX) points to a 25.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research • Oct 28, 2026

Protagonist Therapeutics: The Opt-Out That Turned A Biotech Into A Royalty Compounder

Protagonist Therapeutics has evolved into a royalty-driven company with two FDA-approved drugs, robust liquidity, and a $300 million buyback. PTGX secured lucrative back-end royalties and milestones from Takeda and J&J, shifting risk and execution to partners while retaining substantial economic upside. Consensus forward earnings are nearly 4x trailing levels, underpinned by high-margin royalty streams that could generate $605 million annually against $220 million in expenses.

Seeking Alpha • Oct 25, 2026

Protagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here's What You Should Know

Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research • Oct 15, 2026

Protagonist Therapeutics, Inc. (PTGX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Protagonist Therapeutics, Inc. (PTGX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seeking Alpha • Sep 9, 2026

Protagonist Therapeutics Announces $300 Million Share Repurchase Program

NEWARK, CA / ACCESS Newswire / September 8, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $300 million of its outstanding common stock. The Company intends to fund the share repurchases from its cash, cash equivalents, and marketable securities, and from royalties and other payments received under the Company's collaboration arrangements with Takeda related to MIMRYLOTM (rusfertide) and with Johnson & Johnson related to ICOTYDETM (icotrokinra).

Accesswire • Sep 8, 2026

Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026

NEWARK, CA / ACCESS Newswire / September 2, 2026 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D.

Accesswire • Sep 2, 2026

Protagonist Wins FDA Approval for MIMRYLO in Rare Blood Cancer Treatment

Protagonist Therapeutics NASDAQ: PTGX said the U.S. Food and Drug Administration has approved rusfertide, to be marketed as MIMRYLO, for the treatment of erythrocytosis in adults with polycythemia vera, or PV.

MarketBeat • Aug 31, 2026

Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycythemia Vera Transcript

Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycythemia Vera Transcript

Seeking Alpha • Aug 31, 2026